A Balamuthia survivor

Michael Eric Vollmer¹ and Carol Glaser²

¹Infectious Disease Doctors Medical Group, 365 Lennon Lane Suite 200, Walnut Creek, CA 94598, USA
²The Permanente Medical Group, Oakland Medical Center, 3505 Broadway St, Oakland, CA 94611, USA

Introduction: This case report describes a human survivor of Balamuthia mandrillaris infection. This is a free-living amoeba that can cause infection with the devastating consequence of near universally fatal encephalitis. We report this case to demonstrate the possibility of recovery.

Case presentation: A 26-year-old Hispanic male, a landscape gardener, presented to the hospital in March 2010 with a two month history of headache, visual disturbances and new-onset seizures. Brain imaging identified two enhancing central lesions and Balamuthia mandrillaris was later identified by brain biopsy. He received several months of various antimicrobials including miltefosine, a novel use of the drug in this disease at the time. Seven weeks into therapy, considerations were made to switch him to ‘comfort care’ because of worsening clinical status and seemingly lack of response to treatment. The patient finally demonstrated clinical and radiological improvement after eight weeks with modified therapy, despite experiencing some debilitating toxic effects likely to be related to antibiotics. Two years after his initial presentation he made a complete recovery.

Conclusion: Balamuthia mandrillaris amoebic encephalitis is considered an almost universally fatal disease; this case demonstrates the possibility of recovery. This report outlines his treatment, drug toxicities and includes additional information regarding the therapeutic role of the drug miltefosine. Whether his survival is related to the specific antimicrobials used in this case is unknown and further investigation is warranted.

Keywords: balamuthia; ameba; encephalitis; headache; brain; survivor.

Introduction

This case report describes a human survivor of Balamuthia mandrillaris infection. This is a free-living amoeba that can cause infection with the devastating consequence of near universally fatal encephalitis. Balamuthia mandrillaris was originally described in a pregnant mandrill monkey with encephalitis in 1986 and later identified as a human pathogen in 1990 (Visvesvara et al., 1990). Since then, there have been approximately 200 reports worldwide – mostly from Latin America and the United States. The amoeba naturally inhabits soil and infection appears to occur via respiratory inhalation of aerosolized particles or direct inoculation through breaks in the skin (Deetz, 2003). Diagnosis is often delayed, and a vast majority of identified cases have resulted in death.

We report this case to demonstrate the possibility of recovery. This report outlines the patient’s treatment, drug toxicities and includes additional information regarding the therapeutic role of the drug miltefosine.

Case report

The patient initially presented at an outside hospital emergency room (ER) in 2010 complaining of a few days of visual disturbances (e.g. floaters), light headedness, throbbing headache and syncope. Neuroimaging by computerized tomography (CT) was unremarkable. He was treated for dehydration and discharged. A follow-up magnetic resonance imaging (MRI) was recommended but not done at that time. He represented two days later with a generalized seizure to the same ER, started on phenytoin and was discharged.

Two months later, he presented to our institution with another generalized seizure and a history of persistent
headache. Cerebrospinal fluid (CSF) analysis showed 2 leukocytes $10^6$, 2 red blood cells $10^6$, protein 0.4 g l$^{-1}$, and glucose 3.4 mmol l$^{-1}$. An MRI revealed two distinct cortical lesions: a 2.4 cm $\times$ 2 cm mass in the left frontal lobe and a 1.2 cm $\times$ 1.6 cm mass in the right temporal lobe. Both areas had a moderate to large amount of surrounding vasogenic edema. The patient was originally from Mexico and had been living in California for several years. He worked for an area landscaping company and lived in an urban zone without significant travel or exposure to the California Central Valley.

With this clinical history, he was initially treated empirically for neurocysticercosis with high dose dexamethasone and albendazole. These medications were discontinued approximately a week later when results of serological tests for cysticercosis [enzyme-linked immunosorbent assay (ELISA) IgG serum and CSF) returned negative from the laboratory, and the patient underwent brain biopsy during the second week of hospital stay.

Pathology results from microscopic examination of the brain tissue identified 'numerous protozoan organisms' consistent with amoebic encephalitis. The patient's medications were re-directed to treating an amoebic abscess in the central nervous system by starting fluconazole, pentamidine, flucytosine, and clarithromycin (see Table 1 for a timeline of medications received during hospital stay). Samples from the biopsy were sent concurrently to the Centers for Disease Control (CDC).

Table 1. Timeline of treatment received in hospital

| Medication          | 1   | 2   | 3   | 4   | 5   | 6   | 7   | 8   | 9   | 10  | 11  | 12  | 13  |
|---------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Dexamethasone       |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Albendazole         |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Amphotericin b liposomal |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Metronidazole       |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Voriconazole        |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Sulfadiazine        |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Fluconazole*        |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Pentamidine         |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Flucytosine         |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Clarithromycin      |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Miltefosine†        |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Azithromycin*       |     |     |     |     |     |     |     |     |     |     |     |     |     |
| Tmp-Sulfa‡          |     |     |     |     |     |     |     |     |     |     |     |     |     |

*Received additional 87 weeks.
†Received additional 3 weeks.
‡Received additional 39 weeks.

 showed positive fluorescent labelling for Balamuthia sp. (see Fig. 1). No staining was observed for Naegleria fowleri or Acanthamoeba species. These findings supported the diagnosis of Balamuthia mandrillaris encephalitis. A specific Balamuthia polymerase chain reaction (PCR) assay was also performed at CDC to confirm the diagnosis. Samples from this biopsy specimen were later used to develop the first draft genome sequence of a strain of Balamuthia mandrillaris (Greninger et al., 2015).

Within the first week of treatment, the patient developed atrial fibrillation which was also associated with prolonged QT interval. Clarithromycin was withheld because of concerns for cardiac toxicity. The patient also had mild hepatic enzyme abnormalities at the time, elevated white count, and remained symptomatic with headache and visual changes (floater and eye pain). Over the next week, he developed additional complaints of nausea, headache and itching. In addition, he developed bouts of polyuria and hypotension requiring repeated intravenous fluid boluses. A second cranial MRI was performed on hospital day (HD) 26 (see Fig. 2). The MRI was remarkable for worsening of disease in left occipital and right temporal lobe. At the time of his treatment in 2010, miltefosine was not approved by the U.S. Federal Drug Administration (FDA) for leishmaniasis or any other infection. We submitted a single patient investigational new drug application (IND) for miltefosine in this case, which was approved by the hospital’s institutional review board (IRB). The medication was started three weeks into the patient’s hospital course with one brief treatment interruption, secondary to an international shipping delay. The dose given was 150 mg oral daily. The patient continued to have several medication related side effects during the course of treatment. The main problems
were intractable nausea, renal insufficiency and pancreatitis. This complicated parenteral nutritional support and medication tolerance during hospital stay. The patient’s condition declined during the first six weeks of hospital stay despite directed therapy against *Balamuthia mandrillaris*.

Fifty days into the patient’s hospital stay, the family and treating physicians considered changing treatment goals to ‘comfort care’ due to multiple complications and the patient’s progressive clinical decline. Antibiotics were altered to parenteral administration when possible, with the exception of miltefosine, in a final effort to maximize coverage for this organism and drug penetration into the CNS.

A third MRI was performed (HD# 57) one week later after this medication switch that showed some mild interval improvement in multiple locations and showed a decrease in overall vasogenic oedema. The patient experienced gradual neurological improvement and also had resolution of hepatic, pancreatic and renal abnormalities over the following week, which coincided with treatment modification and the stopping of pentamidine. His nutritional status improved and he was able to tolerate transition of antibiotics to oral route. After almost three months in the hospital, he was discharged home. He completed approximately 114 days of miltefosine therapy with only mild nausea/vomiting as side effect.

After hospital discharge, he also continued trimethoprim-sulfamethoxazole (TMP-SMX) double strength tablet (160 mg TMP-800 mg SMX) twice daily, azithromycin 500 mg daily, and fluconazole 400 mg daily for an additional nine months until repeat MRI imaging showed continued resolution of CNS lesions. TMP-SMX was discontinued although the patient continued azithromycin and fluconazole for another year. Patient appeared to tolerate these final two medications without any problem. The brain MRI two years after presentation showed no evidence of active disease. Antibiotics were stopped at that point. Now off medication completely, the only complaints of the patient are occasional dizziness and minor visual disturbances, with no detectable neurological deficit. The patient returned to work and had a second child with his wife.

**Discussion**

The mortality rate of *Balamuthia mandrillaris* granulomatous encephalitis is very high. Of the 200 reports, only 11 survivors have been described. In a recent report in CID in 2010, Martinez *et al.* summarized seven patients who survived (Martinez *et al.*, 2010). Since that publication, an additional three survivors have been reported including a 2–year–old from Kentucky (Cary *et al.*, 2010), an 80–year–old female from Australia (Doyle *et al.*, 2011), and a 27–year–old male kidney transplant recipient (Orozco, 2011). Of these 11 cases (see Table 2), the age range was 2 to 80 years (median =26 years) and 50% were female. All received varied drug regiments including pentamidine (Schuster & Visvesvara, 1996), fluconazole (Doyle *et al.*, 2011), albendazole (Martinez *et al.*, 2010), itraconazole (Martinez *et al.*, 2010), macrolide (Orozco, 2011), sulfadiazine or TMP-SMX (Sanderson, 2009; Orozco, 2011) and amphotericin (Visvesvara *et al.*, 1990). Three patients also received clorpromazine. Surgical resection of the brain mass was performed in the 10–year–old female from Peru (Seas & Bravo, 2006) and in the 80–year–old female (Doyle *et al.*, 2011) whose lesion was isolated and had a complete resection. The duration of follow-up of these cases varied from three months to more than five years. In most instances an extensive neurological evaluation was not provided but most of these patients had a good outcome and were noted to be normal neurologically (e.g., some noted to have had ‘no significant neurologic sequelae’).

---

**Fig. 1.** (a) Hematoxylin and eosin stain made from tissue biopsy from left frontal lobe brain biopsy. Demonstrates amoebic trophozoites under high power (×1000). These organisms have abundant amphophilic, slightly flocculent cytoplasm containing ingested cellular debris, and small eosinophilic nuclei with prominent nucleoli. (b) Indirect immunofluorescence staining at same magnification with positive fluorescent labelling for *Balamuthia* sp. (photos of CDC slides courtesy of Dr G. S. Visvesvara).

**Fig. 2.** (a) HD#57 Axial T2 weighted magnetic resonance image (MRI) of brain demonstrating area of biopsy in left frontal region and oedema from mass in right temporal. Disease also noted with new satellite lesions seen in left frontal lobe and left parietal lobe. (b) MRI from two years into treatment with resolution of CNS lesions.
Table 2. Eleven survivors of *Balamuthia mandrillaris* since 2010

| Age (Years) | Sex | Drug treatment                                      | Duration of treatment | References                  |
|-------------|-----|----------------------------------------------------|-----------------------|-----------------------------|
| 64          | Male| Pentamidine 4 mg kg<sup>-1</sup> daily             | 18 days               | (Deetz, 2003)               |
|             |     | Trifluoperazine 20 mg daily                        | 18 days               |                             |
|             |     | Clarithromycin 500 mg daily                        | 24 months             |                             |
|             |     | Fluconazole 400 mg daily                           | 60 months             |                             |
|             |     | Sulfadiazine 6 g daily                             | 60 months             |                             |
| 5           | Female| Pentamidine 1 mg kg<sup>-1</sup> daily          | 34 days               | (Deetz, 2003)               |
|             |     | Flucytosine 110 mg kg<sup>-1</sup> daily          | 17 months             |                             |
|             |     | Thioridazine 1 mg kg<sup>-1</sup> daily           | 22 Months             |                             |
|             |     | Clarithromycin 14 mg kg<sup>-1</sup> daily        | 29 months             |                             |
|             |     | Fluconazole 14 mg kg<sup>-1</sup> daily           | 29 months             |                             |
| 72          | Female| Pentamidine 300 mg daily                        | 13 days?              | (Jung, 2004)                |
|             |     | Fluconazole 400 mg daily                          | Not reported           |                             |
|             |     | Sulfadiazine 1.5 gm QID                            | Not reported           |                             |
|             |     | Clarithromycin 500 mg tid                         | Not reported           |                             |
| 35          | Male | Unknown                                            | Lost to follow-up     | (Centers for Disease Control and Prevention, 2008) |
| 8           | Male | Albendazole 400 mg daily                          | 14 months             | (Seas, 2006)                |
|             |     | Itraconazole 200 mg daily                         | 14 months             |                             |
| 10          | Female| Albendazole 600 mg daily                         | 6 months              | (Seas, 2006)                |
|             |     | Itraconazole 100 mg daily                         | 6 months              |                             |
|             |     | Tmp-Smx (320 mg/1600 mg) daily                    | 6 months              |                             |
| 21          | Female| Itraconazole 200 mg daily                        | 10 months             | (Martinez, 2010)            |
|             |     | Albendazole 400 mg daily                          | 10 months             |                             |
|             |     | Albendazole 800 mg daily                          | 7.5 months            |                             |
|             |     | Fluconazole 450 mg daily                          | 7.5 months            |                             |
|             |     | Ambisome 2.85 gram total                          | 2 courses             |                             |
|             |     | Millefosine 150 mg daily × 12, then100 mg daily   | 7 months              |                             |
|             |     | Tmp-Smx (640/3200) daily                          | 45 days               |                             |
|             |     | Clarithromycin 1500 mg daily                      | 14 days               |                             |
|             |     | Artesunate 100 mg daily                           | 14 days               |                             |
| 80          | Female| Pentamidine 300 mg daily                          | 7 days                | (Doyle, 2011)               |
|             |     | Liposomal amphotericin 3 mg kg<sup>-1</sup> daily| 21 days               |                             |
|             |     | Fluconazole 1 gm TID                              | 7 months              |                             |
|             |     | Azithromycin 600 mg daily                         | 7 months              |                             |
|             |     | Itraconazole 200 mg bid                           | 7 months              |                             |
|             |     | Suphadiazine 1.5 mg QID                           | 7 months              |                             |
| 27          | Male | Sulfadiazine (dosages not reported)               | 126 days              | (Orozco, 2011)              |
|             |     | Azithromycin                                      | 126 days              |                             |
|             |     | Miltefosine                                       | 126 days              |                             |
| 2           | Male | Pentamidine 4 mg kg<sup>-1</sup> daily           | Less than 62 days     | (Cary, 2010)                |
Table 2. cont.

| Age (Years) | Sex | Drug treatment                        | Duration of treatment | References |
|-------------|-----|----------------------------------------|-----------------------|------------|
| 26          | Male| Pentamidine 4 mg kg⁻¹ daily             | 29 days               | This case  |
|             |     | Fluconazole 2000 mg bid                 | 33 days               |            |
|             |     | Sulfadiazine 1500 mg oral daily         | 33 days               |            |
|             |     | Miltefosine 150 mg daily                | 114 days              |            |
|             |     | Tmp-Smx 430 mg TID                      | 1 months              |            |
|             |     | - Reduced to 160 mg 800 mg oral bid     | 12 months             |            |
|             |     | Fluconazole 400 mg IV q 12 & daily      | 25 months             |            |
|             |     | Azithromycin 500 mg daily               | 25 months             |            |

Many of the survivors initially received pentamidine. Pentamidine was originally recommended for this infection based on in vitro studies showing some activity against *Balamuthia* (Schuster & Visvesvara, 1996). However, pentamidine has known poor penetration of the blood-brain barrier into the central nervous system (7), and significant clinical toxicity associated with its use. Indeed, the six survivors that received pentamidine had reported toxicity with either hypotension, pancreatitis or severe nausea/gastrointestinal upset. In place of pentamidine, our experience suggests that miltefosine should be considered in any treatment plan. Miltefosine was originally developed as an anti-cancer drug. In recent years, it has been shown to have efficacy against leishmaniasis (Sundar, 2002). Additionally, there are in vitro data showing activity against free-living amoeba, including *Balamuthia* (Schuster et al., 2006). Since this publication, miltefosine has been approved by the FDA for use in the United States for leishmaniasis. We hope that the current lack of commercial availability of the drug can be remedied that could encourage clinicians to contact the CDC to gain access to this medication for off-label use in free-living amoebic infections. Complete surgical resection is also worth considering, particularly in patients with a single brain lesion (Doyle et al., 2011).

Ten of 200 reported cases survived, which is a case fatality rate of 95%. Among the reported survivors, although many were diagnosed relatively late in their disease course, they still had a good outcome. It is possible that if cases were recognized earlier in the course of disease, an even higher proportion of cases would have improved outcomes. We hope by providing details of this case, including the protracted course and delay in clinical response improvement, clinicians will pursue medical therapy in the hope of a potential cure for this predominantly fatal disease.

We acknowledge that the appropriate drugs, dosages, and duration of treatment remain unknown, given the rarity of the *Balamuthia mandrillaris* diagnosis. Improved diagnostic techniques including accurate PCR testing from spinal fluid and specific serologic markers by antigen or antibody detection may prove useful in earlier diagnosis without the need for invasive tissue biopsy. Ongoing research is clearly needed for the development of effective and standardized pharmacotherapy for this disease.

**Acknowledgements**

The authors would like to acknowledge support from the following people: Sandra Eisenlohr (John Muir), Dr Visvesvara (CDC), Mathias Tietras (Aeterna Zentaris Inc), Shigeo Yagi, and Dunnie Dixon. The authors declare that they have no conflict of interest and received no funding support for publication of this paper.

**References**

Cary, L. C., Maul, E., Potter, C., Wong, P., Nelson, P. T., Given, C. & Robertson, W. (2010). *Balamuthia mandrillaris* meningoencephalitis: survival of a pediatric patient. *Pediatrics* 125, e699–e703.

Centers for Disease Control and Prevention (CDC) (2008). *Balamuthia amebic encephalitis*--California, 1999–2007. *MMWR Morb Mortal Wkly Rep* 57, 768–771.

Deetz, T. R., Sawyer, M. H., Schuster, F. L. & Visvesvara, G. S. (2003). Successful treatment of *Balamuthia* amebic encephalitis: presentation of 2 cases. *Clin Infect Dis* 37, 1304–1312.

Doyle, J. S., Campbell, E., Fuller, A., Spelman, D. W., Cameron, R., Malham, G., Gin, D. & Lewin, S. R. (2011). *Balamuthia mandrillaris* brain abscess successfully treated with complete surgical excision and prolonged combination antimicrobial therapy. *J Neurosurg* 114, 458–462.

Greninger, A. L., Messacar, K., Dunnebacke, T., Naccache, S. N., Federman, S., Bouquet, J., Mirskey, D., Nomura, Y., Yagi, S. & other authors (2015). Clinical metagenomic identification of balamuthia.
mandrillaris encephalitis and assembly of the draft genome: the continuing case for reference genome sequencing. Genome Med 7, 113.

Jung, S., Schelper, R. L., Visvesvara, G. S. & Chang, H. T. (2004). Balamuthia mandrillaris meningoencephalitis in an immunocompetent patient: an unusual clinical course and a favorable outcome. Arch Pathol Lab Med 128, 466–468.

Martínez, D. Y., Seas, C., Bravo, F., Legua, P., Ramos, C., Cabello, A. M. & Gotuzzo, E. (2010). Successful treatment of Balamuthia mandrillaris amoebic infection with extensive neurological and cutaneous involvement. Clin Infect Dis 51, e7–e11.

Orozco, L. D., Khan, M. A., Fratkin, J. D. & Hanigan, W. C. (2011). Asymptomatic aneurysm of the cavernous and supraclinoid internal carotid artery in a patient with Balamuthia mandrillaris encephalitis. J Clin Neurosci 18, 1118–1120.

Sanderson, L., Dogruel, M., Rodgers, J., De Koning, H. P. & Thomas, S. A. (2009). Pentamidine movement across the murine blood-brain and bloodcerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. J Pharmacol. 329, 967–977.

Schuster, F. L. & Visvesvara, G. S. (1996). Axenic growth and drug sensitivity studies of Balamuthia mandrillaris, an agent of amebic meningoencephalitis in humans and other animals. J Clin Microbiol 34, 385–388.

Schuster, F. L., Guglielmo, B. J. & Visvesvara, G. S. (2006). In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol 53, 121–126.

Seas, C. & Bravo, F. G. (2006). Encefalitis amebiana granulomatosa por Balamuthia mandrillaris: una enfermedad fatal reconocida cada vez más frecuentemente. Rev Chil Infect 23, 197–199.

Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A. & Berman, J. (2002). Oral miltefosine for Indian Visceral Leishmaniasis. N Engl J Med 347, 1739–1746.

Visvesvara, G. S., Martinez, A. J., Schuster, F. L., Leitch, G. J., Wallace, S. V., Sawyer, T. K. & Anderson, M. (1990). Leptomyxid ameba, a new agent of amebic meningoencephalitis in humans and animals. J Clin Microbiol 28, 2750–2756.